Allosteric modifiers of neuronal nicotinic acetylcholine receptors: New methods, new opportunities

Medicinal Research Reviews

Volumn 27, Issue 5, 2007, Pages 723-753

  Moaddel, Ruin ^a   Jozwiak, Krzysztof ^a,b   Wainer, Irving W ^a,c  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Affinity chromatography; Ethidium binding site; Molecular modeling; Non competitive inhibition; Quinacrine binding site

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 METHOXYMORPHINAN; 4 AMINOBUTYRIC ACID RECEPTOR; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; AZD 0328; CYTISINE; DEXTROMETHORPHAN; DEXTRORPHAN; DRUG METABOLITE; EPIBATIDINE; ETHIDIUM; GLUCOSE TRANSPORTER 1; GLYCOPROTEIN P; ISPRONICLINE; MEM 3454; MEPACRINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR BLOCKING AGENT; NORLEVORPHANOL; ORGANIC CATION TRANSPORTER 1; RECEPTOR SUBTYPE; SSR 180711; TC 1698; TC 1827; TC 2559; TC 2696; TC 5231; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; BINDING AFFINITY; BINDING COMPETITION; COMPETITIVE INHIBITION; COMPUTER MODEL; CONFORMATIONAL TRANSITION; DISSOCIATION CONSTANT; DRUG BINDING SITE; DRUG RECEPTOR BINDING; DRUG SCREENING; HUMAN; IC 50; LIQUID CHROMATOGRAPHY; MOLECULAR INTERACTION; MOLECULAR MODEL; NERVE CELL; NONHUMAN; PROTEIN CONFORMATION; RECEPTOR BLOCKING; REVIEW; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; HUMANS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NICOTINIC ANTAGONISTS; RECEPTORS, NICOTINIC; SEQUENCE ALIGNMENT;

EID: 34548012169     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20091     Document Type: Review

References (76)

1. Gundish D. Nicotinic acetylcholine receptor ligands as potential therapeutics. Expert Opin Ther Patents 2005;15:1221-1239.
2. Buccafusco JJ. Neuronal nicotinic receptor subtypes: Defining therapeutic targets. Mol Intervent 2004;4:285-293.
3. Newhouse P, Singh A, Potter A. Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. Curr Top Med Chem 2004;4:267-282.
4. Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: Beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 2005;326:378-386.
5. Holladay MW, Dart MJ, Lynch JK. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 1997;40:4169-4194.
6. Simosky JK, Stevens KE, Freedman R. Nicotinic agonists and psychosis. Curr Drug Targets CNS Neurol Disord 2002;1:149-162.
7. Sabbagh MN, Lukas RJ, Sparks DL, Reid RT. The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. J Alzheimers Dis 2002;4:317-325.
8. Kern WR, Mahnir VM, Prokai L, Papke RL, Cao X, LeFrancois S, Wildeboer K, Prokai-Tatrai K, Porter-Papke J, Soti F. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2,4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): Their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol 2004;65:56-67.
9. Tassonyi E, Charpantier E, Muller D, Dumont L, Bertrand D. The role of nicotinic acetylcholine receptors in the mechanisms of anesthesia. Brain Res Bull 2002;57:133-150.
10. Dwoskin LP, Crooks PA. Competitive neuronal nicotinic receptor antagonists: A new direction for drug discovery. J Pharmacol Exp Ther 2001;298:395-402.
11. Kenakin T. Allosteric modulators: The new generation of receptor antagonists. Mol Intervent 2004;4:222-229.
12. Friederich P, Dybek A, Urban BW. Stereospecific interaction of ketamine with nicotinic acetylcholine receptors in human sympathetic ganglion-like SH-SY5Y cells. Anesthesiology 2000;93:818-824.
13. Fryer JD, Lukas RJ. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function. J Neurochem 1999;72:1117-1124.
14. George TP, O'Malley SS. Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci 2004;25:42-48.
15. Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol 2002;438:99-105.
16. Papke RL, Sanberg PR, Shytle RD. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. J Pharmacol Exp Ther 2001;297:646-656.
17. Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ. Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. J Pharmacol Exp Ther 2000;293:962-967.
18. Xiao Y, Smith RD, Caruso FS, Kellar KJ. Blockade of rat alpha3beta4 nicotinic receptor function by methadone, its metabolites, and structural analogs. J Pharmacol Exp Ther 2001;299:366-371.
19. Jozwiak K, Haginaka J, Moaddel R, Wainer IW. Displacement and nonlinear chromatographic techniques in the investigation of interaction of noncompetitive inhibitors with an immobilized alpha3beta4 nicotinic acetylcholine receptor liquid chromatographic stationary phase. Anal Chem 2002;74:4618-4624.
20. Jozwiak K, Ravichandran S, Collins JR, Wainer IW. Interaction of noncompetitive inhibitors with an immobilized alpha3beta4 nicotinic acetylcholine receptor investigated by affinity chromatography, quantitative-structure activity relationship analysis, and molecular docking. J Med Chem 2004;47:4008-4021.
21. Jozwiak K, Moaddel R, Yamaguchi R, Ravichandran S, Collins JR, Wainer IW. Qualitative assessment of IC50 values of inhibitors of the neuronal nicotinic acetylcholine receptor using a single chromatographic experiment and multivariate cluster analysis. J Chromatogr B Analyt Technol Biomed Life Sci 2005;819:169-174.
22. Moaddel R, Jozwiak K, Yamaguchi R, Wainer IW. Direct chromatographic determination of dissociation rate constants of ligand-receptor complexes: Assessment of the interaction of noncompetitive inhibitors with an immobilized nicotinic acetylcholine receptor-based liquid chromatography stationary phase. Anal Chem 2005;77:5421-5426.
23. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002;3:102-114.
24. Hucho F, Tsetlin VI, Machold J. The emerging three-dimensional structure of a receptor. The nicotinic acetylcholine receptor. Eur J Biochem 1996;239:539-557.
25. Albuquerque EX, Alkondon M, Pereira EF, Castro NG, Schrattenholz A, Barbosa CT, Bonfante-Cabarcas R, Aracava Y, Eisenberg HM, Maelicke A. Properties of neuronal nicotinic acetylcholine receptors: Pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117-1136.
26. Changeux JP, Galzi JL, Devillers-Thiery A, Bertrand D. The functional architecture of the acetylcholine nicotinic receptor explored by affinity labelling and site-directed mutagenesis. Q Rev Biophys 1992;25:395-432.
27. Millar NS. Assembly and subunit diversity of nicotinic acetylcholine receptors. Biochem Soc Trans 2003;31:869-874.
28. Wang H, Yu M, Ochani M, Amelia CA, Tanovic M, Susarla S, Li JH, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003;421:384-388.
29. Romanelli MN, Gualtieri F. Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications. Med Res Rev 2003;23:393-426.
30. Arias HR. Binding sites for exogenous and endogenous non-competitive inhibitors of the nicotinic acetylcholine receptor. Biochim Biophys Acta 1998;1376:173-220.
31. Auerbach A. Life at the top: The transition state of AChR gating. Sci STKE 2003;2003:re11.
32. Krauss M, Korr D, Herrmann A, Hucho F. Binding properties of agonists and antagonists to distinct allosteric states of the nicotinic acetylcholine receptor are incompatible with a concerted model. J Biol Chem 2000;275:30196-30201.
33. Arias HR. Topology of ligand binding sites on the nicotinic acetylcholine receptor. Brain Res Brain Res Rev 1997;25:133-191.
34. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 1999;288:88-92.
35. Arias HR, McCardy EA, Gallagher MJ, Blanton MP. Interaction of barbiturate analogs with the Torpedo californica nicotinic acetylcholine receptor ion channel. Mol Pharmacol 2001;60:497-506.
36. Ortells MO, Barrantes GE, Wood C, Lunt GG, Barrantes FJ. Molecular modelling of the nicotinic acetylcholine receptor transmembrane region in the open state. Protein Eng 1997;10:511-517.
37. Sankararamakrishnan R, Adcock C, Sansom MS. The pore domain of the nicotinic acetylcholine receptor: Molecular modeling, pore dimensions, and electrostatics. Biophys J 1996;71:1659-1671.
38. + ions in models of the pore region of the nicotinic acetylcholine receptor. Biochem Soc Trans 1997;25:548S.
39. Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature 2003;423:949-955.
40. Oiki S, Danho W, Madison V, Montal M. M2 delta, a candidate for the structure lining the ionic channel of the nicotinic cholinergic receptor. Proc Natl Acad Sci USA 1988;85:8703-8707.
41. Jozwiak K, Hernandez SC, Kellar KJ, Wainer IW. Enantioselective interactions of dextromethorphan and levomethorphan with the alpha 3 beta 4-nicotinic acetylcholine receptor: Comparison of chromatographic and functional data. J Chromatogr B Analyt Technol Biomed Life Sci 2003;797:373-379.
42. Quick MW, Lester RA. Desensitization of neuronal nicotinic receptors. J Neurobiol 2002;53:457-478.
43. Moaddel R, Jozwiak K, Whittington K, Wainer IW. Conformational mobility of immobilized alpha3beta2, alpha3beta4, alpha4beta2, and alpha4beta4 nicotinic acetylcholine receptors. Anal Chem 2005;77:895-901.
44. Wainer I, Jozwiak K, Ravichandran S, Collins JR. Computer-based model for the identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channels, US patent Application No. 10/411,206. 2003.
45. Herz JM, Johnson DA, Taylor P. Interaction of noncompetitive inhibitors with the acetylcholine receptor. The site specificity and spectroscopic properties of ethidium binding. J Biol Chem 1987;262:7238-7247.
46. Bixel MG, Krauss M, Liu Y, Bolognesi ML, Rosini M, Mellor IS, Usherwood PN, Melchiorre C, Nakanishi K, Hucho F. Structure-activity relationship and site of binding of polyamine derivatives at the nicotinic acetylcholine receptor. Eur J Biochem 2000;267:110-120.
47. Pratt MB, Pedersen SE, Cohen JB. Identification of the sites of incorporation of [3H]ethidium diazide within the Torpedo nicotinic acetylcholine receptor ion channel. Biochemistry 2000;39:11452-11462.
48. Park T, Bae S, Choi S, Kang B, Kim K. Inhibition of nicotinic acetylcholine receptors and calcium channels by clozapine in bovine adrenal chromaffin cells. Biochem Pharmacol 2001;61:1011-1019.
49. Chiodini F, Charpantier E, Muller D, Tassonyi E, Fuchs-Buder T, Bertrand D. Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine. Anesthesiology 2001;94:643-651.
50. Exley R, Iturriaga-Vasquez P, Lukas RJ, Sher E, Cassels BK, Bermudez I. Evaluation of benzyltetrahydroisoquinolines as ligands for neuronal nicotinic acetylcholine receptors. Br J Pharmacol 2005;146:15-24.
51. Arias HR. The high-affinity quinacrine binding site is located at a non-annular lipid domain of the nicotinic acetylcholine receptor. Biochim Biophys Acta 1997;1347:9-22.
52. Angal S, Dean PDG. Purification by exploitation of activity. In: Harris E, Angal S, editor. Protein purification methods, a practical approach. Oxford: Oxford University Press; 1989. pp 245-290.
53. Chaiken IM. Analytical affinity chromatography in studies of molecular recognition in biology: A review. J Chromatogr 1986;376:11-32.
54. Wade J, Bergold AF, Carr PW. Theoretical description of nonlinear chromatography, with applications to physicochemical measurements in affinity chromatography and implications for preparative-scale separations. Anal Chem 1987;59:1286-1295.
55. Brekkan E, Lundqvist A, Lundahl P. Immobilized membrane vesicle or proteoliposome affinity chromatography. Frontal analysis of interactions of cytochalasin B and D-glucose with the human red cell glucose transporter. Biochemistry 1996;35:12141-12145.
56. Gottschalk I, Lagerquist C, Zuo SS, Lundqvist A, Lundahl P. Immobilized-biomembrane affinity chromatography for binding studies of membrane proteins. J Chromatogr B Analyt Technol Biomed Life Sci 2002;768:31-40.
57. Pidgeon C, Venkataram UV. Immobilized artificial membrane chromatography: Supports composed of membrane lipids. Anal Biochem 1989;176:36-47.
58. Beigi F, Wainer IW. Syntheses of immobilized G protein-coupled receptor chromatographic stationary phases: Characterization of immobilized mu and kappa opioid receptors. Anal Chem 2003;75:4480-4485.
59. Beigi F, Chakir K, Xiao RP, Wainer IW. G-protein-coupled receptor chromatographic stationary phases. 2. Ligand-induced conformational mobility in an immobilized beta2-adrenergic receptor. Anal Chem 2004;76:7187-7193.
60. Zhang Y, Xiao Y, Kellar KJ, Wainer IW. Immobilized nicotinic receptor stationary phase for on-line liquid chromatographic determination of drug-receptor affinities. Anal Biochem 1998;264:22-25.
61. Moaddel R, Bullock PL, Wainer IW. Development and characterization of an open tubular column containing immobilized P-glycoprotein for rapid on-line screening for P-glycoprotein substrates. J Chromatogr B Analyt Technol Biomed Life Sci 2004;799:255-263.
62. Zhang Y, Leonessa F, Clarke R, Wainer IW. Development of an immobilized P-glycoprotein stationary phase for on-line liquid chromatographic determination of drug-binding affinities. J Chromatogr B Biomed Sci Appl 2000;739:33-37.
63. Moaddel R, Yamaguchi R, Ho PC, Patel S, Hsu CP, Subrahmanyam V, Wainer IW. Development and characterization of an immobilized human organic cation transporter based liquid chromatographic stationary phase. J Chromatogr B Analyt Technol Biomed Life Sci 2005;818:263-268.
64. Moaddel R, Cloix JF, Ertem G, Wainer IW. Multiple receptor liquid chromatographic stationary phases: The co-immobilization of nicotinic receptors, gamma-amino-butyric acid receptors, and N-methyl D-aspartate receptors. Pharm Res 2002;19:104-107.
65. Sevin-Landais A, Rigler P, Tzartos S, Hucho F, Hovius R, Vogel H. Functional immobilisation of the nicotinic acetylcholine receptor in tethered lipid membranes. Biophys Chem 2000;85:141-152.
66. Besanger TR, Easwaramoorthy B, Brennan JD. Entrapment of highly active membrane-bound receptors in macroporous Sol-Gel derived silica. Anal Chem 2004;76:6470-6475.
67. Thomas H. Heterogeneous ion exchange in a flowing system. J Am Chem Soc 1944;66:66-69.
68. Jaulmes A, Vidal-Madjar C. Theoretical aspects of quantitative affinity chromatography: An overview. In: Giddings J, Grushka E, Brown PR, editor. Advances in Chromatography, Vol. 28. New York: Marcel Dekker; 1989. pp 1-64.
69. Bertucci C, Bartolini M, Gotti R, Andrisano V. Drug affinity to immobilized target bio-polymers by high-performance liquid chromatography and capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2003;797:111-129.
70. Hage DS, Austin J. High-performance affinity chromatography and immobilized serum albumin as probes for drug- and hormone-protein binding. J Chromatogr B Biomed Sci Appl 2000;739:39-54.
71. 50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099-3108.
72. Moaddel R, Jozwiak K, Yamaguchi R, Cobello C, Whittington K, Sarkar TK, Basak S, Wainer IW. On-line screening of conformationally constrained nicotines and anabasines for agonist activity at the alpha3beta4- and alpha4beta2- nicotinic acetylcholine receptors using immobilized receptor-based liquid chromatographic stationary phases. J Chromatogr B Analyt Technol Biomed Life Sci 2004;813:235-240.
73. Kroger D, Liley M, Schiweck W, Skerra A, Vogel H. Immobilization of histidine-tagged proteins on gold surfaces using chelator thioalkanes. Biosens Bioelectron 1999;14:155-161.
74. Krusek J, Dittert I, Hendrych T, Hnik P, Horak M, Petrovic M, Sedlacek M, Susankova K, Svobodova L, Tousova K, Ujec E, Vlachova V, Vyklicky L, Vyskocil F, Vyklicky L, Jr. Activation and modulation of ligand-gated ion channels. Physiol Res 2004;53(Suppl 1):S103-S113.
75. Grosman C, Auerbach A. The dissociation of acetylcholine from open nicotinic receptor channels. Proc Natl Acad Sci USA 2001;98:14102-14107.
76. Moaddel R, Hamid R, Patel S, Bullock P, Wainer IW. Identification of P-glycoprotein substrates using open tubular chromatography on an immobilized P-glycoprotein column: Comparison of chromatographic results with Caco-2 permeability. Anal Chim Acta 2006;578:25-30.